Literature DB >> 20800343

Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors.

Molly M Burnett1, Christopher P Hess, John P Roberts, Nathan M Bass, Vanja C Douglas, S Andrew Josephson.   

Abstract

BACKGROUND: Reversible posterior leukoencephalopathy syndrome (RPLS) is a clinico-radiologic diagnosis associated with numerous medical conditions including hypertension, immunosuppressant medications, and eclampsia. It is characterized by headache, altered mental status, seizures, visual disturbance, and neuroimaging consistent with posterior-predominant vasogenic edema. The objective of this study was to characterize the clinical spectrum and outcomes in a large series of RPLS patients, and to compare the presentation of patients taking calcineurin inhibitors (CNIs) to that of other RPLS patients.
METHODS: We reviewed records of patients seen by the neurology and transplant services over an 18-year period. Comorbid conditions, medications, blood pressure, laboratory testing, clinical outcomes, and radiographic findings were collected.
RESULTS: 84 episodes of RPLS were identified in 79 patients. Etiologies included CNIs (43%), hypertension (29%), renal disease (12%), preeclampsia/eclampsia (7%), and chemotherapy (5%). Patients on CNIs had lower blood pressures (p=0.002) and a lower prevalence of headache (p=0.02) compared to RPLS patients with other etiologies. Clinical recovery occurred in 65% of episodes, and radiographic resolution occurred in 67%.
CONCLUSIONS: Patients with CNI-induced RPLS have lower blood pressure than other RPLS patients, but otherwise present similarly. RPLS typically occurs within days to weeks of CNI initiation in patients without elevated medication levels. Clinical and radiographic recovery occurred in the majority of patients in this series, but one-third suffered residual neurologic deficits or death. These findings highlight the importance of prompt recognition and treatment of RPLS triggers to prevent permanent sequelae.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20800343     DOI: 10.1016/j.clineuro.2010.07.023

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  26 in total

1.  Cortical blindness and posterior reversible encephalopathy syndrome in an older patient.

Authors:  Sabrina Ait; Thomas Gilbert; Francois Cotton; Marc Bonnefoy
Journal:  BMJ Case Rep       Date:  2012-05-26

Review 2.  Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2017-05       Impact factor: 5.606

3.  The spectrum of posterior reversible encephalopathy in systemic lupus erythematosus.

Authors:  Amritha Budhoo; Girish M Mody
Journal:  Clin Rheumatol       Date:  2015-08-23       Impact factor: 2.980

4.  Unusual presentation of PRES in the postnatal period.

Authors:  Miriam O'Kane; Hosam Elhalwagy; Sathish Kumar; Claire Badawi
Journal:  BMJ Case Rep       Date:  2014-07-09

Review 5.  [Posterior reversible encephalopathy syndrome].

Authors:  M Fischer; E Schmutzhard
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-06-06       Impact factor: 0.840

6.  Imaging Patterns and Outcome of Posterior Reversible Encephalopathy Syndrome During Childhood Cancer Treatment.

Authors:  Raja B Khan; Zsila S Sadighi; Jennifer Zabrowski; Amar Gajjar; Sima Jeha
Journal:  Pediatr Blood Cancer       Date:  2015-10-15       Impact factor: 3.167

7.  Posterior reversible encephalopathy syndrome due to hypercalcaemia: a rare cause.

Authors:  Nandakrishna Bolanthakodi; Sudha Vidyasagar; Muralidhar Varma; Avinash Holla
Journal:  BMJ Case Rep       Date:  2019-02-11

8.  Posterior reversible encephelopathy syndrome presenting as quadriparesis in pregnancy induced hypertension.

Authors:  Ajit Kumar; Seema Shahi; Debasish Choudhary
Journal:  J Clin Diagn Res       Date:  2015-04-01

9.  Determinants of recovery from severe posterior reversible encephalopathy syndrome.

Authors:  Stephane Legriel; Olivier Schraub; Elie Azoulay; Philippe Hantson; Eric Magalhaes; Isaline Coquet; Cedric Bretonniere; Olivier Gilhodes; Nadia Anguel; Bruno Megarbane; Laurent Benayoun; David Schnell; Gaetan Plantefeve; Julien Charpentier; Laurent Argaud; Bruno Mourvillier; Arnaud Galbois; Ludivine Chalumeau-Lemoine; Michel Rivoal; François Durand; Arnaud Geffroy; Marc Simon; Annabelle Stoclin; Jean-Louis Pallot; Charlotte Arbelot; Martine Nyunga; Olivier Lesieur; Gilles Troché; Fabrice Bruneel; Yves-Sébastien Cordoliani; Jean-Pierre Bedos; Fernando Pico
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

10.  Posterior Reversible Encephalopathy Syndrome Associated with Tacrolimus in Cardiac Transplantation.

Authors:  Julián Alejandro Rivillas; Stephania Galindo-Coral; Francisco Arias-Mora; Juan David Lopez-Ponce de Leon; Noel Alberto Florez-Alarcón; Pastor Olaya-Rojas; Juan Esteban Gomez-Mesa
Journal:  Case Rep Cardiol       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.